Skip Navigation

Cardiovascular Research 2000 47(4):637-639; doi:10.1016/S0008-6363(00)00161-9
© 2000 by European Society of Cardiology
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Cross, H. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cross, H. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

Trimetazidine: a novel protective role via maintenance of Na+/K+-ATPase activity?

Heather R. Cross*

Department of Pathology, Box 3712, Duke University Medical Center, Durham, NC 27710, USA

* Tel.: +1-919-541-5411; fax: +1-919-541-3385 laszlo.deszi{at}richter.hu

Received 14 June 2000; accepted 26 June 2000

See article by El Banani et al. [31] (pages 688–696) in this issue.

Trimetazidine (1-[2,3,4-trimethoxybenzyl]-piperazine; TMZ) is a piperazine compound that has been demonstrated to protect against ischaemic injury in a variety of tissues [1–4]. As a cardiovascular therapeutic agent, TMZ is protective during coronary artery bypass graft surgery [5] and catheter angioplasty [6], has been effective in the treatment of angina [7,8] and reduces infarct size when given before thrombolysis in patients with anterior myocardial infarction [9]. There have been insights into some of the molecular mechanisms of action of TMZ, however, new mechanisms continue to be discovered [10–12]. The best known action of TMZ is inhibition of the β-oxidation pathway of fatty acid metabolism [13]. Inhibition of the β-oxidation pathway during ischaemia and reperfusion concomitantly increases glucose oxidation [13]. Protection from ischaemic injury by TMZ is hypothesized to be due to the increase in glucose oxidation leading to lower rates of glycolysis and less H+ production [14–17]. Increased fatty acid oxidation and glycolysis do result in greater H+ production [18,19] and ischaemic intracellular pH changes have been observed in TMZ-treated hearts [14]. The detrimental effect of glycolytic H+ production in the ischaemic myocardium is thought to be due to increased Na+/H+ exchange activity [20–22]. H+ activate the Na+/H+ exchanger [23], causing Na+ influx. Na+ efflux via the Na+/K+-ATPase is attenuated during ischaemia [24], therefore activation of the Na+/H+ exchanger leads to increased intracellular Na+ [25–27]. The increased intracellular Na+ stimulates Na+/Ca2+ exchange [28], resulting in increased intracellular Ca2+ [25,29] and it is this high Ca2+ which exacerbates myocardial injury [21,25,29,30].

TMZ-mediated alterations in fatty acid and glucose metabolism should therefore lead to changes in ion homeostasis. Specifically, one would predict a decrease in ischaemic intracellular H+, Na+ and Ca2+ with TMZ. In a study published in this issue of Cardiovascular Research, El Banani et al. [31], examined the effects of TMZ on ionic changes during low-flow and zero-flow (total) ischaemia in isolated fatty-acid perfused rat hearts using 31P and 23Na nuclear magnetic resonance (NMR) spectroscopy. Like others, El Banani et al. [31] found perfusion with 1 µM TMZ to be cardioprotective, resulting in a 2-fold increase in post-ischaemic recovery of contractile function after low-flow ischaemia and a 5-fold increase after zero-flow ischaemia. However, they also found that the ionic effects of TMZ differed during low vs. zero-flow ischaemic protocols. In the low-flow ischaemic hearts, TMZ attenuated the ischaemic decrease in intracellular pH, consistent with the predicted attenuation of glycolysis subsequent to inhibition of β-oxidation by TMZ. However, the TMZ-treated low-flow ischaemic hearts did not exhibit an attenuation in ischaemic Na+, implying that TMZ-mediated protection was not via decreased Na+/H+ exchange activity during ischaemia. Also, contrary to the findings in low-flow hearts, there was no effect of TMZ treatment on ischaemic intracellular pH in zero-flow hearts, however, ischaemic Na+ was attenuated. The lack of a pH effect of TMZ in zero-flow hearts may be due to rapid glycolytic inhibition by a faster accumulation of metabolic products in zero vs. low-flow hearts, but in the absence of a pH effect, the role of glycolysis and Na+/H+ exchange activity in TMZ-mediated protection is questioned. During reperfusion, protective effects of TMZ were apparent in both low-flow and zero-flow hearts. In both groups, TMZ treatment resulted in greater increases in LVDP and faster decreases in both LVEDP and intracellular Na+. These findings may imply that TMZ-mediated alterations in glucose metabolism occur primarily during reperfusion, however, the absence of a higher pH during reperfusion in TMZ-treated vs. untreated low or zero-flow hearts again argues against decreased glycolysis as the mechanism of TMZ-mediated protection. Interestingly, positive effects of TMZ have been demonstrated previously in the absence of changes in glycolysis during ischaemia or reperfusion [32]. So how is the protective effect of TMZ mediated if not via changes in glycolysis and H+ production?

An intriguing potential mechanism is implicated by the intracellular Na+ measurements of El Banani et al. [31]. In both low-flow and zero-flow hearts, intracellular Na+ levels during reperfusion were lower in TMZ-treated than in untreated hearts. In fact, in untreated zero-flow hearts, intracellular Na+ increased for the first 7 min of reperfusion, whilst in the TMZ-treated hearts, intracellular Na+ decreased immediately upon reflow (within the first 30-s measurement). Van Emous et al. [33] demonstrated a similar increase in intracellular Na+ during the first few minutes of reperfusion when the Na+/K+-ATPase was inhibited by ouabain. The possibility exists, therefore, that the Na+/K+-ATPase is inhibited in fatty acid-perfused hearts and this inhibition is relieved by TMZ. Interestingly, the Na+/K+-ATPase is reversibly inhibited by palmitoyl carnitine [34] and TMZ, at the same concentration used this study [31], attenuates the ischaemia-induced increase in levels of long chain acyl carnitines, such as palmitoyl carnitine [16]. In addition, unpublished observations from the same laboratory indicate a similar rapid decrease of intracellular Na+ upon reperfusion of fatty-acid perfused hearts treated with etomoxir, a carnitine palmitoyltransferase-1 inhibitor which also decreases long chain acyl carnitines [35]. As inhibition of Na+/K+-ATPase activity leads to increased intracellular Na+ and Ca2+ and exacerbation of injury [24,36,37], maintenance of post-ischaemic Na+/K+-ATPase activity by reduction of acyl carnitine levels by TMZ may explain the beneficial effect of TMZ in the experiments of El Banani et al. [31] and others [32], in the absence of evidence of decreased glycolysis. This hypothesis is consistent with the observation in the El Banani study [31] that LVEDP was lower during reperfusion in TMZ-treated vs. untreated hearts; LVEDP being proportional to intracellular Ca2+ [38]. Maintenance of Na+/K+-ATPase activity during ischaemia in the TMZ-treated zero-flow hearts may also explain the observation of lower ischaemic intracellular Na+ levels in the absence of alterations in pH.

Although the documented increase in glucose oxidation, as well as other reported mechanisms such as decreased myocardial oxygen consumption with lower fatty acid catabolism [39] and TMZ-mediated antioxidant and mitochondrial effects [9–11], may explain some of the protection afforded by TMZ, the findings of El Banani et al. [31] indicate a novel and intriguing potential protective mechanism. Future studies measuring Na+/K+-ATPase activity during ischaemia and reperfusion in TMZ-treated and untreated hearts, concurrent with measurements of glycolysis and glucose oxidation, will determine whether maintenance of Na+/K+-ATPase activity indeed contributes to the protective effects of the powerful therapeutic agent, trimetazidine.


   References
Top
 References
 

  1. Baumert H., Goujon J.M., Richer J.P., et al. Renoprotective effects of trimetazidine against ischaemia–reperfusion injury and cold storage preservation. Transplantation (1999) 68:300–303.[CrossRef][ISI][Medline]
  2. Settaf A., Morin D., Lamchouri F., et al. Trimetazidine ameliorates the hepatic injury associated with ischaemia–reperfusion in rats. Pharmacol Res (1999) 39:211–216.[CrossRef][ISI][Medline]
  3. Tetik C., Ozden A., Calli N., et al. Cytoprotective effect of trimetazidine on 60 minutes of intestinal ischaemia–reperfusion injury in rats. Transplant Int (1999) 12:108–112.[CrossRef][ISI][Medline]
  4. Gil Loyazaga P., Hernandez E., Carricondo F., Simon F., Poch-Broto J. Trimetazidine prevents cochlear lesions induced by intraperitoneal and perilymphatic administration of kainic acid. Brain Res (1999) 826:95–103.[CrossRef][ISI][Medline]
  5. Fabiani J.N., Ponzio O., Emerit I. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg (1992) 3:486–490.
  6. Birand A., Kudaiberdieva G.Z., Batyraliev T.A., Akgul F., Usal A. Effects of trimetazidine on heart rate variability and left ventricular systolic performance in patients with coronary artery disease after percutaneous transluminal angioplasty. Angioplasty (1997) 48:413–422.
  7. Dalla-Volta S., Maraglino G., Della-Valentina P., Viena P., Desideri A. Comparison of trimetazidine with nifedipine in effort angina. A double-blind, crossover study. Cardiovasc Drug Ther (1990) 4:853–860.[CrossRef][ISI][Medline]
  8. Detry J.M., Sellier P., Pennaforte S., et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propanolol in patients with stable angina. Br J Clin Pharmacol (1994) 37:279–288.[ISI][Medline]
  9. Di Pasquale P., Lo Verso P., Bucca V., et al. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results. Cardiovasc Drug Ther (1999) 13:423–428.[CrossRef][ISI][Medline]
  10. Ancerewicz J., Migliavacca E., Carrupt P.A., et al. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. Free Radic Biol Med (1988) 25:113–120.
  11. Morin D., Elimadi A., Sapena R., et al. Evidence for the existence of 3[H]trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore. Br J Pharmacol (1998) 123:1385–1394.[CrossRef][ISI][Medline]
  12. Guarnieri C., Finelli C., Zini M., Muscari C. Effects of trimetazidine on the calcium transport and oxidative phosphorylation of isolated rat heart mitochondria. Basic Res Cardiol (1997) 92:90–95.[ISI][Medline]
  13. Kantor P.F., Lucien A., Kozak R., Lopaschuk G.D. The anti-anginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl CoA thiolase. Circ Res (2000) 86:580–588.[Abstract/Free Full Text]
  14. Lavanchy N., Martin J., Rossi A. Anti-ischemic effects of trimetazidine: 31P NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther (1987) 286:97–110.[ISI][Medline]
  15. Stanley W.C., Lopaschuk G.D., Hall J.L., McCormack J.D. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res (1997) 33:243–257.[Free Full Text]
  16. El Banani H., Bernard M., Cozzone P., James F., Feuvray D. Ionic and metabolic imbalance as potential factors of ischemia–reperfusion injury. Am J Cardiol (1998) 82:25K–29K.[CrossRef][ISI][Medline]
  17. Fantini E., Demaison L., Sentex E., Grynberg A., Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol (1994) 26:949–958.[CrossRef][ISI][Medline]
  18. Neely J.R., Feuvray D. Metabolic products and myocardial ischemia. Am J Pathol (1981) 102:282–291.[Abstract]
  19. Dennis S.C., Gevers W., Opie L.H. Protons in ischaemia: where do they come from; where do they go to? J Mol Cell Cardiol (1991) 23:1077–1086.[CrossRef][ISI][Medline]
  20. Cross H.R., Opie L.H., Radda G.K., Clarke K. Is high glycogen beneficial or detrimental to the ischaemic rat heart? A controversy resolved. Circ Res (1996) 78:482–491.[Abstract/Free Full Text]
  21. Tani M., Neely J.R. Role of intracellular Na+ in Ca2+ overload and depressed recovery of ventricular function of reperfused ischemic rat hearts. Possible involvement of H+–Na+ and Na+–Ca2+ exchange. Circ Res (1989) 65:1045–1056.[Abstract/Free Full Text]
  22. Dizon J., Burkhoff D., Tauskela J., et al. Metabolic inhibition in the perfused rat heart: evidence for glycolytic requirement for normal sodium homeostasis. Am J Physiol (1998) 274:H1082–1089.[ISI][Medline]
  23. Lazdunski M., Frelin C., Vigne P. The sodium/hydrogen exchange system in cardiac cells: its biochemical and pharmacological properties and its role in regulating internal concentrations of sodium and internal pH. J Mol Cell Cardiol (1985) 17:1029–1042.[ISI][Medline]
  24. Cross H.R., Radda G.K., Clarke K. The role of Na+/K+ ATPase activity during low flow ischemia in preventing myocardial injury: A 31P, 23Na+ and 87Rb NMR spectroscopic study. Magn Res Med (1995) 34:673–685.[ISI][Medline]
  25. Murphy E., Perlman M., London R.E., Steenbergen C. Amiloride delays the ischemic-induced rise in cytosolic free calcium. Circ Res (1991) 68:1250–1258.[Abstract/Free Full Text]
  26. Pike M.M., Kitakaze M., Marban E. 23Na NMR measurements of intracellular sodium in intact perfused ferret hearts during ischemia and reperfusion. Am J Physiol (1990) 259:H1767–1773.[ISI][Medline]
  27. Weiss R.G., Lakatta E.G., Gerstenblith G. Effects of amiloride on metabolism and contractility during reoxygenation in perfused rat hearts. Circ Res (1990) 66:1012–1022.[Abstract/Free Full Text]
  28. Cross H.R., Lu L., Steenbergen C., Philipson K.D., Murphy E. Overexpression of the cardiac Na+/Ca2+ exchanger increases susceptibility to ischemia/reperfusion injury in male, but not female, transgenic mice. Circ Res (1998) 83:1215–1223.[Abstract/Free Full Text]
  29. Marban E., Kitakaze M., Koretsune Y., et al. Quantification of [Ca2+]i in perfused hearts. Critical evaluation of the 5F-BAPTA and nuclear magnetic resonance method as applied to the study of ischemia and reperfusion. Circ Res (1990) 66:1255–1267.[Abstract/Free Full Text]
  30. Gao W.D., Atar D., Liu Y., et al. Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res (1997) 80:393–399.[ISI][Medline]
  31. El Banani H., Bernard M., Baetz D., Cabanes E., Cozzone P.J., Lucien A., Feuvray D. Changes in intracellular sodium and pH during ischaemia–reperfusion are attenuated by trimetazide. Comparison between low- and zero-flow ischaemia. Cardiovasc Res (2000) 47:688–696.[Abstract/Free Full Text]
  32. Boucher F.R., Hearse D.J., Opie L.H. Effects of trimetazidine on ischemic contracture in isolated perfused rat hearts. J Cardiovasc Pharmacol (1994) 24:45–49.[ISI][Medline]
  33. Van Emous J.G., Schreur J.H.M., Ruigrok T.J.C., Van Echteld C.J.A. Both Na+/K+-ATPase and Na+/H+ exchange are immediately active upon post-ischemic reperfusion in isolated rat hearts. J Mol Cell Cardiol (1998) 30:337–348.[CrossRef][ISI][Medline]
  34. Tanaka M., Gilbert J., Pappano A.J. Inhibition of sodium pump by L-palmitoylcarnitine in single guinea-pig ventricular myocytes. J Mol Cell Cardiol (1992) 24:711–720.[CrossRef][ISI][Medline]
  35. Kantor P.F., Dyck J.S., Lopaschuk G.D. Fatty acid oxidation in the reperfused ischemic heart. Am J Med Sci (1999) 318:3–14.[CrossRef][ISI][Medline]
  36. Kim M., Akera T. O2 free radicals: cause of ischemia–reperfusion injury to cardiac Na+/K+-ATPase. Am J Physiol (1987) 252:H252–H257.[ISI][Medline]
  37. Murphy E., Aiton J.F., Horres C.R., Lieberman M. Calcium elevation in cultured heart cells: its role in cell injury. Am J Physiol (1983) 245:C316–C321.[ISI][Medline]
  38. Narita H., Nagao T., Sato M., Nakajima H., Kiyomoto A. Ischemia–reperfusion induced elevation of diastolic tension in the isolated guinea-pig heart and the effects of calcium antagonists. Jpn Heart J (1983) 24:277–288.[Medline]
  39. Liu B., El Alaoui-Talibi Z., Clanachan A.S., Schulz R., Lopaschuk G.D. Uncoupling of contractile function from mitochondrial TCA cycle activity and O2 consumption during reperfusion of ischemic rat hearts. Am J Physiol (1996) 270:H72–H80.[ISI][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Cross, H. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cross, H. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?